In spite of great progress in therapeutic practices over the past decade, neither the incidence nor the deaths from cancer have changed over the past thirty years. Existing anticancer drugs have limited efficacy, severe complications, and high costs expensive. Hence, identifying pharmaceutical agents lacking these disadvantages is required.
